A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2026

Primary Completion Date

August 10, 2028

Study Completion Date

August 10, 2028

Conditions
Anorexia Nervosa Restricting TypeBinge-Eating Disorder
Interventions
DRUG

Midomafetamine

Initial dose of 80 or 120 mg midomafetamine HCl administered orally at the start of each of three psychotherapy sessions, followed by a supplemental half-dose of 40 to 60 mg midomafetamine HCl 1.5 to 2.5 hours later, unless contraindicated.

BEHAVIORAL

Non-directive therapy

Non-directive therapy will be conducted during Experimental Sessions.

BEHAVIORAL

Therapy

Therapy will be conducted during Preparatory Sessions and Integrative Sessions.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Lykos Therapeutics

INDUSTRY